Vashisht R, Patel A, Dahm L, Han C, Medders KE, Mowers R et al (2023) Second-line Pharmaceutical treatments for patients with type 2 diabetes. JAMA Netw Open 6(10):e2336613

PubMed  PubMed Central  Google Scholar 

Godinho R, Mega C, Teixeira-de-Lemos E, Carvalho E, Teixeira F, Fernandes R et al (2015) The place of Dipeptidyl Peptidase-4 inhibitors in type 2 diabetes therapeutics: a me too or the Special one antidiabetic class? J Diabetes Res 2015:806979

PubMed  PubMed Central  Google Scholar 

Stoian AP, Sachinidis A, Stoica RA, Nikolic D, Patti AM, Rizvi AA (2020) The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes. Metabolism 109:154295

CAS  PubMed  Google Scholar 

Hupe-Sodmann K, McGregor GP, Bridenbaugh R, Göke R, Göke B, Thole H et al (1995) Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7–36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 58(3):149–156

CAS  PubMed  Google Scholar 

Campbell JE, Drucker DJ (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17(6):819–837

CAS  PubMed  Google Scholar 

Terrell JM, Jacobs TF (2024) Alogliptin. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2024. StatPearls Publishing LLC.

TGA, AusPAR Alogliptin (as benzoate) 2014 [Available from: https://www.tga.gov.au/sites/default/files/auspar-alogliptin-benzoate-140109.pdf

FDA NESINA (alogliptin) tablets 2013 [Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022271s000lbl.pdf

Christopher R, Covington P, Davenport M, Fleck P, Mekki QA, Wann ER et al (2008) Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther 30(3):513–527

CAS  PubMed  Google Scholar 

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease (2007) Am J Kidney Dis 49(2 Suppl 2):S12–154

Davis TM (2014) Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment. Diabetes Obes Metab 16(10):891–899

CAS  PubMed  Google Scholar 

Wu N, An G (2024) A quantitative systems Pharmacology Model of the Incretin hormones GIP and GLP1, Glucagon, glucose, insulin, and the small molecule DPP-4 inhibitor, Linagliptin. J Pharm Sci 113(1):278–289

CAS  PubMed  Google Scholar 

Balazki P, Schaller S, Eissing T, Lehr TA, Physiologically-Based (2020) Quantitative systems Pharmacology Model of the Incretin hormones GLP-1 and GIP and the DPP4 inhibitor sitagliptin. CPT Pharmacometrics Syst Pharmacol 9(6):353–362

Landersdorfer CB, He YL, Jusko WJ (2012) Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes. Br J Clin Pharmacol 73(3):373–390

CAS  PubMed  Google Scholar 

Bosch R, Petrone M, Arends R, Vicini P, Sijbrands EJG, Hoefman S et al (2022) A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP-1 dual agonist. CPT Pharmacometrics Syst Pharmacol 11(3):302–317

CAS  PubMed  Google Scholar 

Bosch R, Petrone M, Arends R, Vicini P, Sijbrands EJG, Hoefman S et al (2024) Characterisation of cotadutide’s dual GLP-1/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology model. Br J Pharmacol 181(12):1874–1885

Shen C, Yang H, Shao W, Zheng L, Zhang W, Xie H et al (2024) Physiologically based pharmacokinetic modeling to unravel the drug-gene interactions of Venlafaxine: based on activity score-dependent metabolism by CYP2D6 and CYP2C19 polymorphisms. Pharm Res 41(4):731–749

Abdel-Ghany MF, Ayad MF, Tadros MM (2017) Enhanced LC-MS/MS analysis of alogliptin and pioglitazone in human plasma: Applied to a preliminary pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 1058:93–101

CAS  PubMed  Google Scholar 

Kelani KM, Rezk MR, Badran OM, Elghobashy MR (2019) Determination of pioglitazone, its metabolite and alogliptin in human plasma by a novel LC-MS/MS method; application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 1132:121803

CAS  PubMed  Google Scholar 

Dudkowski C, Tsai M, Liu J, Zhao Z, Schmidt E, Xie J (2017) The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus. Eur J Clin Pharmacol 73(3):279–288

CAS  PubMed  Google Scholar 

Eliasson B, Möller-Goede D, Eeg-Olofsson K, Wilson C, Cederholm J, Fleck P et al (2012) Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia 55(4):915–925

CAS  PubMed  Google Scholar 

Noda Y, Miyoshi T, Oe H, Ohno Y, Nakamura K, Toh N et al (2013) Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report. Cardiovasc Diabetol 12:8

CAS  PubMed  PubMed Central  Google Scholar 

Liu X, Liu Y, Liu H, Li H, Yang J, Hu P et al (2021) Dipeptidyl-Peptidase-IV inhibitors, Imigliptin and Alogliptin, improve Beta-cell function in type 2 diabetes. Front Endocrinol (Lausanne) 12:694390

PubMed  Google Scholar 

Willmann S, Lippert J, Schmitt W (2005) From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools. Expert Opin Drug Metab Toxicol 1(1):159–168

CAS  PubMed  Google Scholar 

Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57(5):465–480

CAS  PubMed  Google Scholar 

Røge RM, Bagger JI, Alskär O, Kristensen NR, Klim S, Holst JJ et al (2017) Mathematical Modelling of glucose-dependent Insulinotropic polypeptide and glucagon-like Peptide-1 following ingestion of glucose. Basic Clin Pharmacol Toxicol 121(4):290–297

PubMed  Google Scholar 

Jauslin PM, Frey N, Karlsson MO (2011) Modeling of 24-hour glucose and insulin profiles of patients with type 2 diabetes. J Clin Pharmacol 51(2):153–164

CAS  PubMed  Google Scholar 

Shen C, Liang D, Wang X, Shao W, Geng K, Wang X et al (2022) Predictive performance and verification of physiologically based pharmacokinetic model of propylthiouracil. Front Pharmacol 13:1013432

CAS  PubMed  PubMed Central  Google Scholar 

Willmann S, Thelen K, Lippert J (2012) Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim®. J Pharm Pharmacol 64(7):997–1007

CAS  PubMed  Google Scholar 

Li J, Guo HF, Liu C, Zhong Z, Liu L, Liu XD (2015) Prediction of drug disposition in diabetic patients by means of a physiologically based pharmacokinetic model. Clin Pharmacokinet 54(2):179–193

CAS  PubMed  Google Scholar 

Levy G (1994) Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 56(3):248–252

CAS  PubMed  Google Scholar 

Sarashina A, Chiba K, Tatami S, Kato Y (2020) Physiologically based pharmacokinetic model of the DPP-4 inhibitor linagliptin to describe its nonlinear pharmacokinetics in humans. J Pharm Sci 109(7):2336–2344

CAS  PubMed  Google Scholar 

Wu N, An G (2020) Incorporating pharmacological target-mediated Drug Disposition (TMDD) in a whole-body physiologically based pharmacokinetic (PBPK) model of Linagliptin in Rat and Scale-up to Human. Aaps j 22(6):125

CAS  PubMed  Google Scholar 

Landersdorfer CB, He YL, Jusko WJ (2012) Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV. Br J Clin Pharmacol 73(3):391–401

CAS  PubMed  Google Scholar 

Holst JJ, Wewer Albrechtsen NJ, Pedersen J, Knop FK (2017) Glucagon and amino acids are linked in a mutual feedback cycle: the Liver-α-Cell Axis. Diabetes 66(2):235–240

CAS  PubMed  Google Scholar 

Malik PRV, Yeung CHT, Ismaeil S, Advani U, Djie S, Edginton AN (2020) A physiological Approach to Pharmacokinetics in chronic kidney disease. J Clin Pharmacol 60(Suppl 1):S52–s62

CAS  PubMed  Google Scholar 

Tuloup V, Goutelle S, Tod M, Bourguignon L (2023) Evaluation of renal impairment influence on metabolic drug clearance using a Modelling Approach. Clin Pharmacokinet 62(2):307–319

CAS  PubMed  Google Scholar 

Giorda CB, Nada E, Tartaglino B (2014) Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature. Endocrine 46(3):406–419

CAS  PubMed  Google Scholar 

Covington P, Christopher R, Davenport M, Fleck P, Mekki QA, Wann ER et al (2008) Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther 30(3):499–512

CAS  PubMed  Google Scholar 

Karim A, Laurent A, Munsaka M, Wann E, Fleck P, Mekki Q (2009) Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. J Clin Pharmacol 49(10):1210–1219

CAS  PubMed  Google Scholar 

Karim A, Covington P, Christopher R, Davenport M, Fleck P, Li X et al (2010) Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects. Int J Clin Pharmacol Ther 48(1):46–58

CAS  PubMed  Google Scholar 

Bonate PL, Barrett JS, Ait-Oudhia S, Brundage R, Corrigan B, Duffull S e